NRF2 immunolocalization in human breast cancer patients as a prognostic factor

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 241-252

  Onodera, Yoshiaki ^a   Motohashi, Hozumi ^b   Takagi, Kiyoshi ^a   Miki, Yasuhiro ^a   Shibahara, Yukiko ^a   Watanabe, Mika ^c   Ishida, Takanori ^a   Hirakawa, Hisashi ^d   Sasano, Hironobu ^a,c   Yamamoto, Masayuki ^a   Suzuki, Takashi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Breast; Carcinoma; Immunohistochemistry; NRF2; Prognosis; Proliferation

Indexed keywords

KI 67 ANTIGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CELL ACTIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; IN VITRO STUDY; LABELING INDEX; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; PROTEIN EXPRESSION;

BREAST; CARCINOMA; IMMUNOHISTOCHEMISTRY; NRF2; PROGNOSIS; PROLIFERATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MIDDLE AGED; NF-E2-RELATED FACTOR 2; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84899865579     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0234     Document Type: Article

References (57)

1. Artus C, Maquarre E, Moubarak RS, Delettre C, Jasmin C, Susin SA & Robert-Lézénès J 2006 CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathway in human erythroleukemia cells. Oncogene 25 5741-5751. (doi:10.1038/sj.onc.1209581)
2. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ & Paesmans M 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. British Journal of Cancer 96 1504-1513. (doi:10.1038/sj.bjc.6603756)
3. Baird L & Dinkova-Kostova AT 2011 The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology 85 241-272. (doi:10.1007/s00204-011- 0674-5)
4. Becks L, Prince M, Burson H, Christophe C, Broadway M, Itoh K, Yamamoto M, Mathis M, Orchard E, Shi R et al. 2010 Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7, 12-dimethylbenz[a]anthracene. BMC Cancer 10 540. (doi:10.1186/1471-2407-10-540)
5. Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B & Zheng W 2010 Nrf2 expression in endometrial serous carcinomas and its precancers. International Journal of Clinical and Experimental Pathology 24 85-96.
6. Cheng Y, Li J, Martinka M & Li G 2010 The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kB p105/p50 in human cutaneous melanomas. Oncology Reports 23 973-979. (doi:10.3892/or-00000722)
7. Choi J, Jung W & Koo JS 2013 Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 62 275-286. (doi:10.1111/his.12002)
8. Ciani B, Layfield R, Cavey JR, Sheppard PW & Searle MS 2003 Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. Journal of Biological Chemistry 278 37409-37412. (doi:10.1074/jbc.M307416200)
9. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES et al. 2011 Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 106-109. (doi:10.1038/nature10189)
10. van Diest PJ, van der Wall E & Baak JP 2004 Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology 57 675-681. (doi:10.1136/jcp.2003.010777)
11. Dikic I, Johansen T & Kirkin V 2010 Selective autophagy in cancer development and therapy. Cancer Research 70 3431-3434. (doi:10.1158/0008-5472. CAN-09-4027)
12. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2011 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 28 2784-2795. (doi:10.1200/JCO.2009.25. 6529)
13. Hartikainen JM, Tengström M, Kosma VM, Kinnula VL, Mannermaa A & Soini Y 2012 Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. Cancer Research 72 5537-5546. (doi:10.1158/0008-5472.CAN-12-1474)
14. Hong YB, Kang HJ, Kwon SY, Kim HJ, Kwon KY, Cho CH, Lee JM, Kallakury BV & Bae I 2010 Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 39 463-472. (doi:10.1097/MPA. 0b013e3181c31314)
15. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G et al. 2008 Systemic spread is an early step in breast cancer. Cancer Cell 13 58-68. (doi:10.1016/j.ccr.2007.12. 003)
16. Iida S, Miki Y, Ono K, Akahira J, Nakamura Y, Suzuki T & Sasano H 2012 Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. Molecular and Cellular Endocrinology 350 99-106. (doi:10.1016/j.mce. 2011.11.024)
17. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M et al. 2011 Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. Journal of Cell Biology 193 275-284. (doi:10.1083/jcb.201102031)
18. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A et al. 2012 Accumulationof p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Science 103 760-766. (doi:10.1111/j.1349-7006.2012.02216.x)
19. Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, Mattson J, Villman K, Vrtel R, Lukas J et al. 2012 NQO1 expression correlates inversely with NFkB activation in human breast cancer. Breast Cancer Research and Treatment 132 955-968. (doi:10.1007/s10549-011-1629-5)
20. Karihtala P, Kauppila S, Soini Y & Arja-Jukkola-Vuorinen 2011 Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 11 262. (doi:10.1186/1471-2407-11-262)
21. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG & Kang KW 2008 Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radical Biology & Medicine 45 537-546. (doi:10.1016/j.freeradbiomed.2008.05.011)
22. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y & Kwak MK 2011 NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1a. Cancer Research 71 2260-2275. (doi:10.1158/0008-5472.CAN-10-3007)
23. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI et al. 2010 The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature Cell Biology 12 213-223. (doi:10.3892/or-00000722)
24. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL & Cannistra SA 2011 Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Research 71 5081-5089. (doi:10.1158/0008-5472.CAN-10-4668)
25. Lau A, Villeneuve NF, Sun Z, Wong PK & Zhang DD 2008 Dual roles of Nrf2 in cancer. Pharmacological Research 58 262-270. (doi:10.1016/j.phrs. 2008.09.003)
26. Lewis KN, Mele J, Hornsby PJ & Buffenstein R 2012 Stress resistance in the naked mole-rat: the bare essentials-A mini-review. Gerontology 58 453-462. (doi:10.1159/000335966)
27. Liang CC, Park AY & Guan JL 2007 In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2 329-333. (doi:10.1038/nprot.2007.30)
28. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP et al. 2011 Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer 10 37. (doi:10.1186/1476-4598-10-37)
29. Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, Mann K, Basik M, Bouchard A, Fiset PO et al. 2009 Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Molecular Cancer Therapeutics 8 2432-2440. (doi:10.1158/1535-7163.MCT-08-1186)
30. Miki Y, Nakata T, Suzuki T, Darnel AD, Moriya T, Kaneko C, Hidaka K, Shiotsu Y, Kusaka H & Sasano H 2002 Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. Journal of Clinical Endocrinology and Metabolism 87 5760-5768. (doi:10.1210/jc.2002-020670)
31. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M & Motohashi H 2012 Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 66-79. (doi:10.1016/j.ccr.2012.05.016)
32. Nakamura K, Kimple AJ, Siderovski DP & Johnson GL 2010 PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kB activation. Journal of Biological Chemistry 285 2077-2089. (doi:10.1074/jbc.M109.065102)
33. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826. (doi:10.1056/NEJMoa041588)
34. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R & Spendlove I 2007 The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocrine-Related Cancer 14 73-80. (doi:10.1677/erc.1.01312)
35. Saw CL & Kong AN 2011 Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer. Expert Opinion on Therapeutic Targets 15 281-295. (doi:10.1517/14728222.2011.553602)
36. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR & Wooten MW 2004 Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Molecular and Cellular Biology 24 8055-8068. (doi:10.1128/MCB.24.18.8055-8068.2004)
37. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M & Hirohashi S 2008 Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135 1358-1368. (doi:10.1053/j.gastro.2008.06.082)
38. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T et al. 2011 NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13 864-873. (doi:10.1593/neo.11750)
39. Siegel D & Ross D 2000 Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biology & Medicine 29 246-253. (doi:10.1016/S0891-5849(00)00310-5)
40. Singh B & Bhat HK 2012 Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer. Carcinogenesis 33 2601-2610. (doi:10.1093/carcin/bgs300)
41. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH et al. 2008 RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Research 68 7975-7984. (doi:10.1158/0008-5472.CAN-08-1401)
42. Singh B, Ronghe AM, Chatterjee A, Bhat NK & Bhat HK 2013 MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis 34 1165-1172. (doi:10.1093/carcin/bgt026)
43. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN et al. 2010 Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clinical Cancer Research 16 3743-3753. (doi:10.1158/1078-0432.CCR-09-3352)
44. Surh YJ, Kundu JK & Na HK 2008 Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Medica 74 1526-1539. (doi:10.1055/s-0028-1088302)
45. Suzuki T, Miki Y, Fukuda T, Nakata T, Moriya T & Sasano H 2005 Analysis for localization of steroid sulfatase in human tissues. Methods in Enzymology 400 303-316. (doi:10.1016/S0076-6879(05)00018-2)
46. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007a Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocrine-Related Cancer 14 279-292. (doi:10.1677/ERC-06- 0005)
47. Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S & Sasano H 2007b Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Science 98 644-651. (doi:10.1111/j.1349-7006.2007. 00444.x)
48. Taguchi K, Motohashi H & Yamamoto M 2011 Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes to Cells: Devoted to Molecular & Cellular Mechanisms 16 123-140. (doi:10.1111/j.1365- 2443.2010.01473.x)
49. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD & Sparano JA 2013 Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119 1140-1148. (doi:10.1002/cncr.27819)
50. Uruno A & Motohashi H 2011 The Keap1-Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide 25 153-160. (doi:10.1016/j.niox.2011.02.007)
51. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW et al. 2008 Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute 100 207-212. (doi:10.1093/jnci/djm289)
52. Wakai T, Shirai Y, Sakata J, Matsuda Y, Korita PV, Takamura M, Ajioka Y & Hatakeyama K 2011 Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma. International Journal of Clinical and Experimental Pathology 4 363-370.
53. Wang J, Zhang M, Zhang L, Cai H, Zhou S, Zhang J & Wang Y 2010 Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. Journal of Surgical Research 164 99-105. (doi:10.1016/j.jss.2010.05.058)
54. Wang HB, Zhou CJ, Song SZ, Chen P, Xu WH, Liu B, Zhu KX, Yu WH, Wu HL, Wang HJ et al. 2011 Evaluation of Nrf2 and IGF-1 expression in benign, premalignant and malignant gastric lesions. Pathology, Research and Practice 207 169-173. (doi:10.1016/j.prp.2010.12.009)
55. Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT & Moscat J 2005 The p62 scaffold regulates nerve growth factor-induced NF-kB activation by influencing TRAF6 polyubiquitination. Journal of Biological Chemistry 280 35625-35629. (doi:10.1074/jbc.C500237200)
56. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG & Biswal S 2010 Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics 9 336-346. (doi:10.1158/1535-7163.MCT-09-0589)
57. Zhang X, Su Y, Zhang M & Sun Z 2012 Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo. Cancer Letters 318 93-98. (doi:10.1016/j.canlet.2011.12.005)